Third Harmonic Bio Inc (THRD) Stock Price, Forecast & Analysis
USA - NASDAQ:THRD - US88427A1079 - Common Stock
THRD Key Statistics, Chart & Performance
The current stock price of THRD is 5.38 USD. In the past month the price decreased by -0.55%. In the past year, price decreased by -51.58%.
THRD Latest News, Press Relases and Analysis
THRD Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 46.62 | 970.39B | ||
| JNJ | JOHNSON & JOHNSON | 18.88 | 471.87B | ||
| MRK | MERCK & CO. INC. | 10.55 | 232.09B | ||
| PFE | PFIZER INC | 7.83 | 142.48B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 7.11 | 94.95B | ||
| ZTS | ZOETIS INC | 19.06 | 53.55B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 9.53 | 22.84B | ||
| VTRS | VIATRIS INC | 4.6 | 12.50B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 21.97 | 10.48B | ||
| CORT | CORCEPT THERAPEUTICS INC | 85.84 | 7.96B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 6.97B | ||
| LGND | LIGAND PHARMACEUTICALS | 27.55 | 3.94B |
Related stock screener links
About THRD
Company Profile
Third Harmonic Bio, Inc. develops pharmaceutical products for the treatment of allergic and immune diseases and disorders. The company is headquartered in San Francisco, California and currently employs 53 full-time employees. The company went IPO on 2022-09-15. The firm is focused on advancing the next wave of medicine for inflammatory diseases through the development of novel, small-molecule inhibitors of KIT, a cell surface receptor that serves as the master regulator of mast cell function and survival. The company is developing medicine for the treatment of inflammatory diseases, including dermal, respiratory, and gastrointestinal diseases. Its lead product candidate, THB335, is a titratable, oral, small molecule inhibitor. Dysfunctional mast cell activity has been implicated in the pathophysiology of a broad range of mast cell driven inflammatory disorders, including urticaria, asthma and gastrointestinal disorders, among others. THB335 maintains the nonclinical pharmacology and selectivity profile of THB001, with structural modifications that are designed to functionally block the site of reactive metabolite formation to mitigate hepatotoxicity risk.
Company Info
Third Harmonic Bio Inc
1700 Montgomery Street, Suite 210
San Francisco CALIFORNIA US
Employees: 42
Phone: 12097272457
Third Harmonic Bio Inc / THRD FAQ
What does THRD do?
Third Harmonic Bio, Inc. develops pharmaceutical products for the treatment of allergic and immune diseases and disorders. The company is headquartered in San Francisco, California and currently employs 53 full-time employees. The company went IPO on 2022-09-15. The firm is focused on advancing the next wave of medicine for inflammatory diseases through the development of novel, small-molecule inhibitors of KIT, a cell surface receptor that serves as the master regulator of mast cell function and survival. The company is developing medicine for the treatment of inflammatory diseases, including dermal, respiratory, and gastrointestinal diseases. Its lead product candidate, THB335, is a titratable, oral, small molecule inhibitor. Dysfunctional mast cell activity has been implicated in the pathophysiology of a broad range of mast cell driven inflammatory disorders, including urticaria, asthma and gastrointestinal disorders, among others. THB335 maintains the nonclinical pharmacology and selectivity profile of THB001, with structural modifications that are designed to functionally block the site of reactive metabolite formation to mitigate hepatotoxicity risk.
What is the stock price of Third Harmonic Bio Inc today?
The current stock price of THRD is 5.38 USD. The price decreased by -0.09% in the last trading session.
What is the dividend status of Third Harmonic Bio Inc?
THRD does not pay a dividend.
What is the ChartMill rating of Third Harmonic Bio Inc stock?
THRD has a ChartMill Technical rating of 2 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
On which exchange is THRD stock listed?
THRD stock is listed on the Nasdaq exchange.
Can you provide the number of employees for Third Harmonic Bio Inc?
Third Harmonic Bio Inc (THRD) currently has 42 employees.
What is the market capitalization of THRD stock?
Third Harmonic Bio Inc (THRD) has a market capitalization of 242.80M USD. This makes THRD a Micro Cap stock.
THRD Technical Analysis
ChartMill assigns a technical rating of 2 / 10 to THRD. When comparing the yearly performance of all stocks, THRD is a bad performer in the overall market: 90.71% of all stocks are doing better.
THRD Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to THRD. THRD has a great financial health rating, but its profitability evaluates not so good.
THRD Financial Highlights
Over the last trailing twelve months THRD reported a non-GAAP Earnings per Share(EPS) of -1.42. The EPS decreased by -89.33% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -19.1% | ||
| ROE | -19.6% | ||
| Debt/Equity | 0 |
THRD Forecast & Estimates
6 analysts have analysed THRD and the average price target is 3.06 USD. This implies a price decrease of -43.12% is expected in the next year compared to the current price of 5.38.